Bullish Moving Averages
11
Bearish Moving Averages
5
Back Stocks profile
Stock analysis tool for investors
Open an Account with Bigul in 5 minutes
Performance
Today’s low
6795.60Today’s High
6915.0052W low
4250.0052W High
7572.20Open Price
6915.00Prev. Close
6902.7500Volume
2725.00Value
18585590.00Fundamentals
Market Cap
17051.00
Price to Earnings
177.90
Price to Book Value
24.00
Dividend Yield
0.40
PE to Growth
-6.40
Op Revenue TTM
1387.58
Net Profit TTM
95.86
Cash From Operating Activity
27.87
Return on Equity %
22.68
EMA & SMA
DELIVERY AND VOLUME
DAILY AVG. DELIVERY VOLUME %
12 Sep, 2024
49.2
Week
20.2
Month
29.7
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
6865.22
PIVOT
First Resistance
6929.08
Second Resistance
7030.27
Third Resistance
7094.13
First Support
6764.03
Second Support
6700.17
Third Support
6598.98
Relative Strength Index
52.09
Money Flow Index
79.38
MACD
38.19
MACD Signal
28.74
Average True Range
241.96
Average Directional Index
22.86
Rate of Change (21)
3.53
Rate of Change (125)
27.03
Day Commodity Channel Index
45.7
Day Williams %R
-51.2
BETA
1 Month
-0.16
3 Month
0.77
1 Year
0.72
3 Year
0.31
PRICE CHANGE ANALYSIS
↓ -1.01%
1 Week
Low
High
6719.65
7309.9
↑ 4.36%
1 Month
Low
High
6367.55
7309.9
↑ 7.53%
3 Months
Low
High
6069.7
7572.2
↑ 31.92%
6 Months
Low
High
4785
7572.2
↑ 52.23%
1 Year
Low
High
4250
7572.2
| Indicator | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 395.87 | 391.86 | 315.45 | 319.44 | 303.57 | 292.70 | 257.00 | 242.92 | 236.45 | 235.65 | 205.86 | 200.55 | 178.30 | |
| Operating Expenses Qtr | 349.44 | 333.81 | 290.73 | 258.31 | 228.22 | 224.85 | 213.22 | 195.40 | 204.37 | 194.00 | 185.86 | 179.79 | 159.77 | |
| Operating Profit Qtr | 38.08 | 49.39 | 15.06 | 52.76 | 67.25 | 59.85 | 36.59 | 40.72 | 27.96 | 37.96 | 14.67 | 17.92 | 15.63 | |
| EBIDT Qtr Cr | -11.13 | 58.05 | 24.72 | 77.56 | 75.35 | 27.62 | 43.79 | 47.52 | 32.08 | 41.64 | 20.00 | 20.76 | 18.53 | |
| Depreciation Qtr | 3.91 | 3.76 | 3.70 | 3.67 | 3.80 | 4.25 | 4.13 | 3.29 | 4.59 | 4.41 | 3.51 | 4.28 | 4.76 | |
| Net Profit Qtr | -11.79 | 39.48 | 15.80 | 52.37 | 53.86 | 17.27 | 29.30 | 32.56 | 20.15 | 27.98 | 11.42 | 11.95 | 10.24 | |
| Basic EPS Qtr | -4.72 | 15.79 | 6.32 | 20.95 | 21.54 | 6.91 | 11.72 | 13.03 | 8.06 | 11.19 | 4.57 | 4.78 | 4.10 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 1330.33 | 1029.07 | 820.36 | 826.40 | 844.80 | |
| Operating Expenses Annual Cr | 1111.08 | 837.85 | 719.42 | 678.09 | 711.11 | |
| Operating Profit Annual | 184.45 | 165.12 | 86.18 | 135.47 | 120.70 | |
| Operating Profit Margin Annual % | 13.86 | 16.05 | 10.51 | 16.39 | 14.29 | |
| Total Expenses Annual Cr | 1127.22 | 854.74 | 737.32 | 699.31 | 730.83 | |
| EBIDT Annual Cr | 219.25 | 191.22 | 100.94 | 148.31 | 133.69 | |
| EBIDT Annual margin % | 16.48 | 18.58 | 12.30 | 17.95 | 15.83 | |
| Depreciation | 14.94 | 16.26 | 16.95 | 20.13 | 18.58 | |
| PAT Before ExtraOrdinary Items Annual Cr | 161.51 | 99.29 | 61.60 | 93.30 | 72.21 | |
| Net Profit Annual | 161.51 | 99.29 | 61.60 | 93.30 | 72.21 | |
| Basic EPS Annual | 64.60 | 39.70 | 24.60 | 37.30 | 28.90 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 711.92 | 588.69 | 511.39 | 456.17 | 364.44 | |
| Minority Interest Liability Annual Cr | - | - | - | - | - | |
| Total Non Current Liabilities Annual Cr | 8.99 | 12.25 | 12.52 | 15.04 | 14.68 | |
| Total Current Liabilities Annual Cr | 357.12 | 383.93 | 332.65 | 303.50 | 327.24 | |
| Total Capital Plus Liabilities Annual Cr | 1078.03 | 984.87 | 856.56 | 774.71 | 706.36 | |
| Fixed Assets Annual | 66.95 | 70.19 | 76.69 | 84.98 | 95.77 | |
| Total Non Current Assets Annual | 145.32 | 149.40 | 150.89 | 155.95 | 164.04 | |
| Total Current Assets Annual | 932.71 | 835.47 | 705.67 | 618.76 | 542.32 | |
| Total Assets Annual | 1078.03 | 984.87 | 856.56 | 774.71 | 706.36 | |
| Contingent Liabilities plus Commitments Annual Cr | 138.25 | 132.28 | 124.60 | 89.17 | 69.19 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | 27.87 | 58.29 | 100.80 | 104.78 | 87.42 | |
| Cash from Investing Activity Annual | 21.74 | 18.11 | 4.74 | 173.03 | -170.80 | |
| Cash from Financing Annual Activity | -44.38 | -24.48 | -9.46 | -8.97 | -6.36 | |
| Net Cash Flow Annual | 5.23 | 51.92 | 96.08 | 268.84 | -89.74 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 284.77 | 235.48 | 204.56 | 182.47 | 145.78 | |
| ROE Annual % | 22.68 | 16.86 | 12.04 | 20.45 | 19.81 | |
| ROCE Annual % | 28.34 | 29.11 | 16.03 | 27.20 | 30.36 | |
| Total Debt to Total Equity Annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EBDIT Annual Margin % | 16.92 | 19.06 | 12.52 | 18.22 | 16.07 |
| Indicator | Graph |
|---|---|
| Total Qtr Revenue cr | |
| Operating Expenses Qtr | |
| Operating Profit Qtr | |
| EBIDT Qtr Cr | |
| Depreciation Qtr | |
| Net Profit Qtr | |
| Basic EPS Qtr |
| Indicator | Graph |
|---|---|
| Total Revenue Annual | |
| Operating Expenses Annual Cr | |
| Operating Profit Annual | |
| Operating Profit Margin Annual % | |
| Total Expenses Annual Cr | |
| EBIDT Annual Cr | |
| EBIDT Annual margin % | |
| Depreciation | |
| PAT Before ExtraOrdinary Items Annual Cr | |
| Net Profit Annual | |
| Basic EPS Annual |
| Indicator | Graph |
|---|---|
| Total ShareHolders Funds Annual | |
| Minority Interest Liability Annual Cr | |
| Total Non Current Liabilities Annual Cr | |
| Total Current Liabilities Annual Cr | |
| Total Capital Plus Liabilities Annual Cr | |
| Fixed Assets Annual | |
| Total Non Current Assets Annual | |
| Total Current Assets Annual | |
| Total Assets Annual | |
| Contingent Liabilities plus Commitments Annual Cr |
| Indicator | Graph |
|---|---|
| Cash from Operating Activity Annual | |
| Cash from Investing Activity Annual | |
| Cash from Financing Annual Activity | |
| Net Cash Flow Annual |
| Indicator | Graph |
|---|---|
| Book Value Per Share Annual | |
| ROE Annual % | |
| ROCE Annual % | |
| Total Debt to Total Equity Annual | |
| EBDIT Annual Margin % |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| ICICI PRUDENTIAL (VARIOUS SCHEMES) | 1.53 | 89009270 | - | - |
| SHIVANI TEJAS TRIVEDI | 2.4 | 89009289 | - | - |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| AstraZeneca Pharmaceuticals AB | 75 | 89009266 | 0 | 0 |
| Name | Holding Percent | Holding Id |
|---|---|---|
| NIPPON LIFE INDIA (VARIOUS SCHEMES) | 2.91 | 89009269 |
| ICICI PRUDENTIAL (VARIOUS SCHEMES) | 1.53 | 89009270 |
| Name | Holding Percent | Holding Id |
|---|---|---|
| TEJAS BHALCHANDRA TRIVEDI | 2.68 | 89009288 |
| SHIVANI TEJAS TRIVEDI | 2.4 | 89009289 |
| Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
| Jul 05, 2024 | 24 | FINAL | Jul 05, 2024 | Equity Share |
| Jul 14, 2023 | 16 | FINAL | Jul 14, 2023 | Equity Share |
| Jul 07, 2022 | 8 | FINAL | Jul 08, 2022 | Equity Share |
| Aug 18, 2021 | 2 | INTERIM | Aug 20, 2021 | Equity Share |
| Aug 20, 2020 | 2 | INTERIM | Aug 21, 2020 | Equity Share |
| Aug 20, 2019 | 1 | INTERIM | Aug 21, 2019 | Equity Share |
| Jul 09, 2012 | 3.5 | FINAL | - | Equity Share |
| Jul 07, 2011 | 10 | FINAL | - | Equity Share |
| May 06, 2010 | 10 | FINAL | - | Equity Share |
| Apr 29, 2009 | 15 | FINAL | - | Equity Share |
| Apr 11, 2008 | 15 | FINAL | - | Equity Share |
| Mar 22, 2007 | 12 | INTERIM | Mar 24, 2007 | Equity Share |
| Apr 12, 2006 | 20 | FINAL | - | Equity Share |
| Mar 18, 2005 | 50 | FINAL | - | Equity Share |
| Apr 16, 2004 | 3.9 | FINAL | - | Equity Share |
| Apr 17, 2003 | 3.7 | FINAL | - | Equity Share |
| May 15, 2002 | - | FINAL | - | Equity Share |
| Jun 18, 2001 | - | FINAL | - | Equity Share |
| Aug 11, 2000 | - | FINAL | - | Equity Share |
| Ex-Date | Split Ratio | Record Date |
|---|---|---|
| Jun 15, 2006 | 10:2 | 2006-06-22 |
| Ex-Date | Purpose | Notes |
|---|---|---|
| Aug 08, 2024 | Quarterly Results | - |
| May 27, 2024 | Audited Results & Dividend | - |
| Feb 08, 2024 | Quarterly Results | - |
| Nov 09, 2023 | Quarterly Results | - |
| Aug 14, 2023 | Quarterly Results | - |
| May 30, 2023 | Audited Results & Dividend | - |
| Feb 10, 2023 | Quarterly Results | - |
| Nov 11, 2022 | Quarterly Results | - |
| Aug 08, 2022 | Quarterly Results | - |
| May 26, 2022 | Audited Results & Final Dividend | - |
| Feb 08, 2022 | Quarterly Results | - |
| Nov 09, 2021 | Quarterly Results | - |
| Aug 09, 2021 | Quarterly Results & Interim Dividend | - |
| May 25, 2021 | Audited Results | - |
| Feb 08, 2021 | Quarterly Results | - |
| Nov 05, 2020 | Quarterly Results | - |
| Aug 10, 2020 | Quarterly Results & Interim Dividend | - |
| May 18, 2020 | Audited Results | - |
| Feb 03, 2020 | Quarterly Results | - |
| Nov 11, 2019 | Quarterly Results | - |
| Aug 07, 2019 | Quarterly Results & Interim Dividend | - |
| May 24, 2019 | Audited Results | - |
| Feb 06, 2019 | Quarterly Results | - |
| Nov 13, 2018 | Quarterly Results | - |
| Aug 13, 2018 | Unaudited Financial Results | - |
| May 21, 2018 | Audited Results | - |
| Feb 05, 2018 | Quarterly Results | - |
| Nov 06, 2017 | Quarterly Results | - |
| Aug 08, 2017 | Quarterly Results | - |
| May 09, 2017 | Audited Results | - |
| Feb 02, 2017 | Quarterly Results | - |
| Dec 02, 2016 | Others | Mr. Rajesh Marwaha, Chief Financial Officer of the Company hasbeen inducted into the board as Additional and Whole-time Director. His profile is attached. |
| Nov 11, 2016 | Quarterly Results | - |
| Aug 09, 2016 | Quarterly Results | - |
| May 25, 2016 | Audited Results | - |
| Feb 06, 2016 | Quarterly Results & Others | The Board of Directors approved the re-appointment of Mr. Sanjay Murdeshwar as Managing Director of the Company for a period of 3 years, to be effective from May 02, 2016. |
| Dec 02, 2015 | Others | Decided to close the Active Pharmaceutical Ingredient Unit (API Unit) situated at 12th Mile on Bellary Road,Venkatala, Yelahanka, Bangalore - 560063. |
| Nov 06, 2015 | Quarterly Results & Others | The Board appointed Ms. Claire-Marie O' Grady as Director of the Company in the vacancy caused by the resignation of Ms. Rebekah Martin with immediate effect. |
| Aug 04, 2015 | Quarterly Results | - |
| May 27, 2015 | Audited Results | - |
| Feb 11, 2015 | Quarterly Results | - |
| Nov 03, 2014 | Quarterly Results | - |
| Aug 12, 2014 | Quarterly Results | - |
| May 30, 2014 | Audited Results | - |
| May 05, 2014 | Others | To consider seeking approval of shareholders of the Company through Postal Ballot, for the voluntary delisting proposed by AstraZeneca Pharmaceuticals AB Sweden,Promoter of the company. |
| Apr 15, 2014 | Others | To consider for the voluntary delisting proposed by AstraZeneca Pharmaceuticals Promoter of the Company, in terms of Securities and Exchange Board of India, through Postal Ballot. |
| Mar 15, 2014 | Others | To consider the voluntary delisting proposal from AstraZeneca Pharmaceuticals AB, Sweden in terms of their letter dated March 01, 2014 at the meeting of the BOD of the Company held on March 15,2014. |
| Mar 05, 2014 | Others | - |
| Feb 10, 2014 | Quarterly Results | - |
| Nov 11, 2013 | Quarterly Results | - |
| Aug 13, 2013 | Quarterly Results | - |
| May 21, 2013 | Audited Results | - |
| May 06, 2013 | Others | - |
| May 02, 2013 | Quarterly Results | - |
| Feb 06, 2013 | Quarterly Results | - |
| Nov 07, 2012 | Quarterly Results | - |
| Aug 10, 2012 | Quarterly Results | - |
| May 11, 2012 | Audited & Quarterly Results | - |
| Feb 02, 2012 | Quarterly Results | - |
| Nov 10, 2011 | Quarterly Results | - |
| Aug 08, 2011 | Quarterly Results | - |
| Jun 14, 2011 | Others | inter alia, to consider and approve the proposal of straightening of land boundaries of factory with IDL Industries Ltd. |
| May 13, 2011 | Audited Results & Dividend | Fifteen Months. |
| Feb 08, 2011 | Quarterly Results | - |
| Oct 27, 2010 | Quarterly Results | - |
| Jul 27, 2010 | Quarterly Results & Others | For seeking the consent / approval of the Shareholders of the Company through postal ballot to the delisting proposal initiated by AstraZeneca Pharmaceuticals, AB, Sweden, promoter of the Company. |
| Jul 09, 2010 | Others | The Board has deferred the decision on delisting proposal initiated by AstraZeneca Pharmaceuticals AB Sweden, promoter of the Company. |
| Jun 29, 2010 | Voluntary Delisting of Shares | To make a voluntary delisting offer to the public Shareholders of the Co. in accordance with the SEBI (DES) Regulations, 2009 with a view to delist the Equity Shares from BSE, NSE & BgSE. |
| Apr 27, 2010 | Others | The Board has appointed Ms. Anita Zutshi as the Chief Financial Officer of the Company. |
| Apr 26, 2010 | Quarterly Results | - |
| Mar 25, 2010 | Others | 1. Proposal to augment the Co's Tablet manufacturing plant and facility involving an estimated aggregate outlay of Rs. 70 Crs. 2. Appointment of Mr. Luigi Felice La Corte, as an Additional Director. |
| Feb 23, 2010 | Audited Results, Dividend & Others | The Board has approved the change in the accounting year of the Company from "January-December" to "April-March" & Recommended a Dividend of Rs. 10/- per Equity Share of face value of Rs. 2/- each. |
| Oct 27, 2009 | Quarterly Results | - |
| Jul 27, 2009 | Quarterly Results | - |
| Apr 23, 2009 | Quarterly Results | - |
| Feb 18, 2009 | Audited Results & Dividend | - |
| Oct 23, 2008 | Quarterly Results | - |
| Jul 29, 2008 | Quarterly Results | - |
| Apr 28, 2008 | Quarterly Results | - |
| Feb 25, 2008 | Audited Results & Dividend | - |
| Oct 26, 2007 | Quarterly Results | - |
| Jul 26, 2007 | Quarterly Results | - |
| Apr 30, 2007 | Quarterly Results | - |
| Mar 17, 2007 | Interim Dividend | To consider the approval of the revised Audited Accounts for the financial year ended December 31, 2006, after incorporating necessary changes as to the revocation of recommended dividend & others. |
| Feb 23, 2007 | Accounts & Dividend | - |
| Oct 28, 2006 | Quarterly Results | - |
| Sep 08, 2006 | Issue of fully paid bonus debentures | Inter alia, to consider a proposal for issue by the Company of secured fully paid bonus debentures from its General Reserve in terms of a Scheme of Arrangement between the Company and its Shareholders |
| Aug 28, 2006 | Issue of fully paid bonus debentures | To consider a proposal for issue by the Company of secured fully paid bonus debentures from its General Reserve in terms of a Scheme of Arrangement between the Company and its Shareholders. (deferred) |
| Jul 28, 2006 | Quarterly Results | - |
| May 09, 2006 | Sub Division of Equity shares | - |
| Apr 29, 2006 | Quarterly Results | - |
| Feb 23, 2006 | Accounts & Dividend | - |
| Oct 20, 2005 | Quarterly Results | (Revised) |
| Aug 24, 2005 | Accounts | - |
| Apr 27, 2005 | Quarterly Results | - |
| Feb 16, 2005 | Accounts & Dividend | (Revised) |
| Oct 30, 2004 | Quarterly Results | - |
| Aug 16, 2004 | Quarterly Results | - |
| May 31, 2004 | Quarterly Results | (Revised) |
| Apr 21, 2004 | Others | Mr. Bhasker V. Iyer was appinted as an additional Director and Managing Director w.e.f. 06-05-2004. |
| Mar 04, 2004 | Others | Astra Pharmaceuticals AB(APAB) a promoter of the company, held 56.50% of the voting share capital of the company in March, 2002. |
| Feb 24, 2004 | Dividend & Accounts | - |
| Nov 26, 2003 | Quarterly Results | - |
| Aug 26, 2003 | Quarterly Results | - |
| Apr 28, 2003 | Quarterly Results | - |
| Feb 27, 2003 | Dividend, Accounts & Quarterly Results | - |
| Oct 29, 2002 | Quarterly Results | - |
| May 28, 2002 | Quarterly Results | - |
| Mar 14, 2002 | Accounts & Dividend (9 months) | - |
| Oct 17, 2001 | Quarterly Results | - |
| Jul 30, 2001 | Quarterly Results | - |
| Jul 19, 2001 | Quarterly Results | (Cancelled) |
| May 17, 2001 | Qtr Results, Dividend & Accounts | - |
| Jan 18, 2001 | Quarterly Results | - |
| Oct 31, 2000 | Quarterly Results | - |
| Jul 12, 2000 | Quarterly Results | - |
| Mar 30, 2000 | Interim Dividend | - |
| Jan 29, 2000 | Quarterly Results | - |
| Jan 19, 2000 | Quarterly Results | - |
| Oct 22, 1999 | Quarterly Results | - |
| Jul 21, 1999 | Quarterly Results | - |
| Apr 20, 1999 | Quarterly Results | - |
| Jan 28, 1999 | Quarterly Results | - |
| Oct 27, 1998 | Quarterly Results | - |
| Jul 28, 1998 | Quaterly Results | - |
| Jun 26, 1998 | Accounts & Dividend | - |
| May 27, 1998 | Half Yearly Results | - |
| Nov 11, 1997 | Half Yearly Results | - |
| Jun 18, 1997 | Accounts & Dividend | - |
| Ex-Date | Bonus Ratio | Record Date |
|---|
12 Sep 2024
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Closure of Trading Window
This is to inform you that, in accordance with the provisions of SEBI (PIT) Regulations, 2015, read with the Company''s Code of Conduct for Prevention of Insider Trading, the trading window for dealing in the Equity Shares of the Company will be closed from September 16, 2024 and the same shall reopen after 48 hours from the declaration of un-audited financial results of the Company for the quarter ending September 30, 2024.
12 Sep 2024
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (LODR) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agents have informed the Company on the enclosed request for Loss of Share Certificate from the legal representative of the claimant.
09 Sep 2024
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith the certificate dated September 4, 2024 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
04 Sep 2024
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (LODR) Regulations, 2015, we would like to inform you that the Registrar and Share Transfer Agents of the Company have informed the Company on the enclosed request for Loss of Share Certificate from the legal representative of the claimant.
27 Aug 2024
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Information Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we would like to inform that Dr. Anil Arjundas Kukreja, currently the Vice-President - Medical Affairs and Regulatory at AstraZeneca Pharma India Limited has decided to pursue his career outside the organisation. He will complete his handover period by the close of business hours on September 30, 2024. The Company is looking for a suitable replacement for the said position. We wish Dr. Anil Kukreja all the best in his future endeavours.
23 Aug 2024
AstraZeneca warns of shifting UK vaccine production to US: Report
An AztraZeneca spokesperson said there are no discussions in the US or India as the company is committed to pursuing the opportunity at Speke and are in constructive talks with the UK government
12 Aug 2024
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find the enclosed copy of the newspaper publication of the unaudited financial results for the quarter ended June 30, 2024.
12 Aug 2024
CEOs of Britain's biggest companies get record pay in 2023, shows research
The highest-paid British CEO was Pascal Soriot of drugmaker AstraZeneca,
09 Aug 2024
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Please find the enclosed Voting Results and the Scrutinizer''s Report of 45th Annual General Meeting of the Company held on August 8, 2024.
08 Aug 2024
AstraZeneca reports Q1 net loss of Rs 12 cr, total income at Rs 396 cr
AstraZeneca Pharma India on Thursday said its net loss stood at Rs 12 crore for the first quarter ended June 30, 2024. The drug maker had reported a net profit of Rs 54 crore in the April-June quarter of last fiscal. Total income stood at Rs 396 crore for the June quarter against Rs 303 crore in the year-ago period, AstraZeneca Pharma India said in a regulatory filing. "We are focused on our ambition to ensure our therapies reach the patients who need them the most and are constantly working to tailor sustainable programmes focused on early diagnosis and improved access to meet local needs by collaborating with healthcare systems, payers, policymakers and non-government organisations," AstraZeneca India Country President and Managing Director Sanjeev Panchal said. Shares of AstraZeneca Pharma on Thursday ended 6.77 per cent lower at Rs 6,613.40 apiece on the BSE.
